US overactive bladder drug market poised for robust growth with new products and expanding patient population

The USA's overactive bladder (OAB) treatment market is slated to witness strong growth, fuelled by the increase in diagnosed patient population, the rollout of new products, and growing awareness, according to a new report from Frost & Sullivan.

The risk for OAB is greatest in Americans that are 65 and older. The population that is in this age bracket is expected to increase by 20.9%, from 38.7 million in 2008 to 46.8 million in 2015. Furthermore, the US Census Bureau reports that the fastest growing segment of the population is for those aged 85 and above.

"Currently all of the Food and Drug Administration approved medications for the treatment of OAB are in the same class of drugs, and patients who cannot take these drugs are excluded from all medicinal options," notes the analyst of this research service, adding: "Innovative therapies that are in a new class and address unmet needs have the potential to therefore expand the OAB market."